As of May 27
| +0.25 / +2.13%|
The 4 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 15.00, with a high estimate of 19.00 and a low estimate of 15.00. The median estimate represents a +25.42% increase from the last price of 11.96.
The current consensus among 4 polled investment analysts is to Buy stock in Amicus Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.